Case Report

Case Report: Homozygous C677T MTHFR Gene Mutation in Male with Hypogonadism

Rami Salameh, Mumtaheena Miah, and Catherine Anastasopoulou

Endocrinology Department, Albert Einstein Medical Center-Philadelphia, Philadelphia, PA, USA

Correspondence should be addressed to Rami Salameh; rami_salameh@hotmail.com

Received 21 May 2019; Accepted 17 March 2020; Published 19 May 2020

Academic Editor: Hyunsik Kang

Copyright © 2020 Rami Salameh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report a 44-year-old male, who was diagnosed with hypogonadotropic hypogonadism after complaining of erectile dysfunction, depression, and fatigue. He was started on testosterone replacement therapy. He persistently complained of fatigue despite increasing the dose of testosterone over two years and having therapeutic testosterone levels on labs while on therapy.

At that point, he underwent genetic testing, as per patient personal request, which showed homozygous C677T MTHFR gene mutation. Other relevant labs included folate: 3.1 ng/mL (normal range: 4.2–19.9) and B12: 333 pg/mL (normal range: 210–934).

His hemoglobin was at normal levels, but interestingly, it did not increase as expected with the use of testosterone.

The patient was treated with folate and B12 supplements, which made his symptoms resolve completely (Table 1).

3. Discussion

MTHFR is a key enzyme in the folate pathway, and it plays an essential role in homocysteine metabolism, as shown in Figure 1.

Homozygous C677T individuals have decreased activity of MTHFR enzyme, thus having an increased risk for hyperhomocysteinemia when deficient in folate, vitamin
B12, or pyridoxine [1]. Elevated homocysteine levels are associated with increased risk of venous thromboembolism, strokes, coronary artery disease, and recurrent pregnancy loss [2]. The exact cause of accelerated vascular disease is unclear, but several mechanisms have been suggested, including endothelial cell damage, lipid peroxidation, smooth muscle cell proliferation, downregulation of antithrombotic factors, and upregulation of prothrombotic factors.

Male hypogonadism, defined as decreased testosterone production and/or impaired ability to produce functional sperms, overlaps with male infertility. The association between C677T variant and male infertility has been reported in the literature.

While some studies did not find an association between C677T polymorphism and male infertility [3, 4], Bezold et al. [5] reported that the prevalence of the homozygous C677T mutation was 18.8% in infertile males as compared with 9.5% in normal fertile males. Thus, it was concluded that MTHFR products may play a role in the pathogenesis of male infertility

Mfady et al. [6] showed that in Jordanians, MTHFR C677T polymorphism was associated with male infertility, while MTHFR A1298C was not. Similar results were reported by Park et al. [7] in the South Korean population.

Gong et al. [8] conducted a meta-analysis on 26 studies involving 5,575 cases and 5,447 controls. MTHFR C677T polymorphism was significantly associated with male infertility in Asians as well as in Caucasians.

Other studies, on the other hand, concluded that there is an association between C677T variant and male infertility in Indian, African, and Southeast Asian populations. Data from Europe regarding this association are conflicting. The lack of similar association in Western populations could be due to the overall dietary enrichment with folates [9].

Lombardo et al. [10] studied the role of C677T MTHFR mutation with subsequent hyperhomocysteinemia in erectile dysfunction. He concluded that hyperhomocysteinemia in homozygous C677T patients may interfere with erection mechanisms and thus cause erectile dysfunction.

Patients identified to have hyperhomocysteinemia should be treated with B-complex vitamin supplements. Initiation of therapy with folic acid, B12, and B6 vitamins tends to normalize homocysteine in 1-2 months. It is unclear whether normalization of homocysteine would improve male infertility or not.

4. Conclusion

Our case emphasizes other important etiologies for fatigue and erectile dysfunction in a male with hypogonadism on testosterone therapy as well as shows the possible association between MTHFR gene mutation and male hypogonadism.

Disclosure

This abstract was presented as a poster in AACE 2019 Meeting in Los Angeles.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References